ONCO Onconetix, Inc.
Price Chart
Executive Summary
Onconetix provided a Q1 2026 operational update highlighting new clinical publications for Proclarix®, initiation of the PRIME study with Labcorp, and European commercial expansion. No financial results were disclosed, and the company did not report revenue or EPS, making this a non-financial pipeline update.
Actionable Insight
Monitor enrollment progress in the PRIME study and any subsequent U.S. regulatory pathway updates. Without financial data, near-term stock movement is likely driven by binary clinical/regulatory catalysts rather than fundamentals.
Key Facts
- Two new peer-reviewed publications in BMC Cancer and Cancers reinforce Proclarix® performance in reducing overdiagnosis and unnecessary biopsies.
- PRIME study initiated with Labcorp to evaluate Proclarix® in the U.S. market; up to 500 men to be enrolled.
- European commercial expansion: ~100 Proclarix® tests conducted in Q1 2026 via a UK screening initiative; collaboration partner identified in Turkey.
- No financial results (revenue, EPS, cash position) were disclosed in the press release.
Financial Impact
No financial figures disclosed; impact depends on future commercialization milestones.
Risk Factors
- Proclarix® is not yet approved for sale in the U.S.; clinical validation and regulatory pathway remain uncertain.
- No revenue or cash runway disclosed; capital needs may require future dilutive financing.
- Historical stock performance shows extreme volatility and negative drift post-filing; prior bullish calls have underperformed significantly.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294088 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 19, 2026
21d ago
|
Press Release
| $1.18 $1.20 | ▼ −1.70% | ▲ +0.54% | $1.01 (+14.41%) |
|
May 13, 2026
27d ago
|
Press Release
| $3.87 $1.10 | ▼ −71.58% | ▼ −71.44% | $1.01 (−73.90%) |
|
May 8, 2026
4w ago
|
EFFECT
| $3.80 $3.74 | ▲ +1.58% | ▲ +1.79% | $1.01 (+73.42%) |
|
May 7, 2026
4w ago
|
S-1/A
| $4.04 $3.90 | ▼ −3.47% | ▼ −5.76% | $1.01 (−75.00%) |
|
Apr 24, 2026
6w ago
|
8-K
| $7.42 $6.47 | ▼ −12.83% | ▼ −13.23% | $1.01 (−86.39%) |
|
Apr 16, 2026
7w ago
|
3
| $7.60 $6.66 | ▼ −12.32% | ▼ −13.30% | $1.01 (−86.71%) |
|
Apr 9, 2026
8w ago
|
PRESS-RELEASE / 425
| $12.20 $7.60 | ▼ −37.70% | ▼ −40.89% | $1.01 (−91.72%) |
|
Apr 2, 2026
9w ago
|
PRESS-RELEASE / 425
| $15.20 $10.90 | ▼ −28.29% | ▼ −31.91% | $1.01 (−93.36%) |
|
Mar 31, 2026
10w ago
|
425
| $14.90 $11.30 | ▼ −24.16% | ▼ −28.11% | $1.01 (−93.22%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $14.90 $11.30 | ▼ −24.16% | ▼ −28.11% | $1.01 (−93.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access